GLAXO SMITHKLINE SELLS RIGHTS TO NOVARTIS AG OF DRUG USED IN TREATING AUTOIMMUNE DISEASES
LONDON— GlaxoSmithKline PLC is selling its remaining rights to a drug for use in treating autoimmune diseases, including multiple sclerosis, to Novartis AG for up to $1 billion, plus royalties. Glaxo … Read More